NCT07289763 Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
| NCT ID | NCT07289763 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Guangdong Hengrui Pharmaceutical Co., Ltd |
| Condition | Primary Membranous Nephropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-12-31 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 75 participants in total. It began in 2025-12-31 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years, regardless of gender; 2. Weight ≥40.0 kg at screening; 3. Diagnosed as primary membranous nephropathy through kidney biopsy. Exclusion Criteria: 1. Secondary membranous nephropathy. 2. Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation. 3. Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period. 4. Subjects who have a malignant tumor or a history of malignant tumor 5. Subjects who have undergone major surgery within the previous 3 months, or plan to undergo major surgery during the study period.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07289763 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Primary Membranous Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07289763 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07289763 currently recruiting?
Yes, NCT07289763 is actively recruiting participants. Contact the research team at zhe.zhang@hengrui.com for enrollment information.
Where is the NCT07289763 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT07289763 clinical trial?
NCT07289763 is sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. The trial plans to enroll 75 participants.